Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study

Phyllis C. Tien, Michael Schneider, Stephen R. Cole, Alexandra M. Levine, Mardge Cohen, Jack Dehovitz, Mary Young, Jessica E. Justman

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To determine the incidence of diabetes mellitus (DM) in a nationally representative cohort of HIV-infected women and a comparison group of HIV-uninfected women. DESIGN: A prospective study between October 2000 and March 2006 of 2088 participants from the Women's Interagency HIV Study who did not have evidence of DM at enrollment (1524 HIV infected and 564 HIV uninfected). METHODS: Incident DM was defined as either having fasting glucose ≥ 1.26 g/l, reporting antidiabetic medication, or reporting DM diagnosis (with subsequent confirmation by fasting glucose ≥ 1.26 g/l or reported antidiabetic medication); all were assessed at semi-annual study visits. RESULTS: DM developed in 116 HIV-infected and 36 HIV-uninfected women over 6802 person-years. HIV-infected women reporting no recent antiretroviral therapy had a DM incidence rate of 1.53/100 person-years; those reporting HAART containing a protease inhibitor (PI) had a rate of 2.50/100 person-years and those reporting non-PI-containing HAART a rate of 2.89/100 person-years. None of these rates differed from the HIV-uninfected women (1.96/100 person-years) substantially or beyond levels expected by chance. Among HIV-infected women, longer cumulative exposure to nucleoside reverse transcriptase inhibitors (NRTI) was associated with an increased risk of DM incidence compared with no NRTI exposure: relative hazard (RH) 1.81 [95% confidence interval (CI), 0.83-3.93] for > 0 to 3 years exposure and RH 2.64 (95% CI, 1.11-6.32) for > 3 years exposure. CONCLUSION: Longer cumulative exposure to NRTI was associated with increased DM incidence in HIV-infected women. Regular DM monitoring is advisable because NRTI form the backbone of effective antiretroviral therapy.

Original languageEnglish (US)
Pages (from-to)1739-1745
Number of pages7
JournalAIDS
Volume21
Issue number13
DOIs
StatePublished - Aug 2007

Fingerprint

Implosive Therapy
Diabetes Mellitus
HIV
Incidence
Reverse Transcriptase Inhibitors
Nucleosides
Highly Active Antiretroviral Therapy
Hypoglycemic Agents
Fasting
Confidence Intervals
Glucose
Protease Inhibitors

Keywords

  • Antiretroviral therapy
  • Diabetes mellitus
  • Fasting glucose
  • HIV
  • Nucleoside reverse transcriptase inhibitor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Tien, P. C., Schneider, M., Cole, S. R., Levine, A. M., Cohen, M., Dehovitz, J., ... Justman, J. E. (2007). Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS, 21(13), 1739-1745. https://doi.org/10.1097/QAD.0b013e32827038d0

Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. / Tien, Phyllis C.; Schneider, Michael; Cole, Stephen R.; Levine, Alexandra M.; Cohen, Mardge; Dehovitz, Jack; Young, Mary; Justman, Jessica E.

In: AIDS, Vol. 21, No. 13, 08.2007, p. 1739-1745.

Research output: Contribution to journalArticle

Tien, PC, Schneider, M, Cole, SR, Levine, AM, Cohen, M, Dehovitz, J, Young, M & Justman, JE 2007, 'Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study', AIDS, vol. 21, no. 13, pp. 1739-1745. https://doi.org/10.1097/QAD.0b013e32827038d0
Tien, Phyllis C. ; Schneider, Michael ; Cole, Stephen R. ; Levine, Alexandra M. ; Cohen, Mardge ; Dehovitz, Jack ; Young, Mary ; Justman, Jessica E. / Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. In: AIDS. 2007 ; Vol. 21, No. 13. pp. 1739-1745.
@article{e41a5ca2e95a41a2b486e6cd1f2e9b04,
title = "Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study",
abstract = "OBJECTIVE: To determine the incidence of diabetes mellitus (DM) in a nationally representative cohort of HIV-infected women and a comparison group of HIV-uninfected women. DESIGN: A prospective study between October 2000 and March 2006 of 2088 participants from the Women's Interagency HIV Study who did not have evidence of DM at enrollment (1524 HIV infected and 564 HIV uninfected). METHODS: Incident DM was defined as either having fasting glucose ≥ 1.26 g/l, reporting antidiabetic medication, or reporting DM diagnosis (with subsequent confirmation by fasting glucose ≥ 1.26 g/l or reported antidiabetic medication); all were assessed at semi-annual study visits. RESULTS: DM developed in 116 HIV-infected and 36 HIV-uninfected women over 6802 person-years. HIV-infected women reporting no recent antiretroviral therapy had a DM incidence rate of 1.53/100 person-years; those reporting HAART containing a protease inhibitor (PI) had a rate of 2.50/100 person-years and those reporting non-PI-containing HAART a rate of 2.89/100 person-years. None of these rates differed from the HIV-uninfected women (1.96/100 person-years) substantially or beyond levels expected by chance. Among HIV-infected women, longer cumulative exposure to nucleoside reverse transcriptase inhibitors (NRTI) was associated with an increased risk of DM incidence compared with no NRTI exposure: relative hazard (RH) 1.81 [95{\%} confidence interval (CI), 0.83-3.93] for > 0 to 3 years exposure and RH 2.64 (95{\%} CI, 1.11-6.32) for > 3 years exposure. CONCLUSION: Longer cumulative exposure to NRTI was associated with increased DM incidence in HIV-infected women. Regular DM monitoring is advisable because NRTI form the backbone of effective antiretroviral therapy.",
keywords = "Antiretroviral therapy, Diabetes mellitus, Fasting glucose, HIV, Nucleoside reverse transcriptase inhibitor",
author = "Tien, {Phyllis C.} and Michael Schneider and Cole, {Stephen R.} and Levine, {Alexandra M.} and Mardge Cohen and Jack Dehovitz and Mary Young and Justman, {Jessica E.}",
year = "2007",
month = "8",
doi = "10.1097/QAD.0b013e32827038d0",
language = "English (US)",
volume = "21",
pages = "1739--1745",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study

AU - Tien, Phyllis C.

AU - Schneider, Michael

AU - Cole, Stephen R.

AU - Levine, Alexandra M.

AU - Cohen, Mardge

AU - Dehovitz, Jack

AU - Young, Mary

AU - Justman, Jessica E.

PY - 2007/8

Y1 - 2007/8

N2 - OBJECTIVE: To determine the incidence of diabetes mellitus (DM) in a nationally representative cohort of HIV-infected women and a comparison group of HIV-uninfected women. DESIGN: A prospective study between October 2000 and March 2006 of 2088 participants from the Women's Interagency HIV Study who did not have evidence of DM at enrollment (1524 HIV infected and 564 HIV uninfected). METHODS: Incident DM was defined as either having fasting glucose ≥ 1.26 g/l, reporting antidiabetic medication, or reporting DM diagnosis (with subsequent confirmation by fasting glucose ≥ 1.26 g/l or reported antidiabetic medication); all were assessed at semi-annual study visits. RESULTS: DM developed in 116 HIV-infected and 36 HIV-uninfected women over 6802 person-years. HIV-infected women reporting no recent antiretroviral therapy had a DM incidence rate of 1.53/100 person-years; those reporting HAART containing a protease inhibitor (PI) had a rate of 2.50/100 person-years and those reporting non-PI-containing HAART a rate of 2.89/100 person-years. None of these rates differed from the HIV-uninfected women (1.96/100 person-years) substantially or beyond levels expected by chance. Among HIV-infected women, longer cumulative exposure to nucleoside reverse transcriptase inhibitors (NRTI) was associated with an increased risk of DM incidence compared with no NRTI exposure: relative hazard (RH) 1.81 [95% confidence interval (CI), 0.83-3.93] for > 0 to 3 years exposure and RH 2.64 (95% CI, 1.11-6.32) for > 3 years exposure. CONCLUSION: Longer cumulative exposure to NRTI was associated with increased DM incidence in HIV-infected women. Regular DM monitoring is advisable because NRTI form the backbone of effective antiretroviral therapy.

AB - OBJECTIVE: To determine the incidence of diabetes mellitus (DM) in a nationally representative cohort of HIV-infected women and a comparison group of HIV-uninfected women. DESIGN: A prospective study between October 2000 and March 2006 of 2088 participants from the Women's Interagency HIV Study who did not have evidence of DM at enrollment (1524 HIV infected and 564 HIV uninfected). METHODS: Incident DM was defined as either having fasting glucose ≥ 1.26 g/l, reporting antidiabetic medication, or reporting DM diagnosis (with subsequent confirmation by fasting glucose ≥ 1.26 g/l or reported antidiabetic medication); all were assessed at semi-annual study visits. RESULTS: DM developed in 116 HIV-infected and 36 HIV-uninfected women over 6802 person-years. HIV-infected women reporting no recent antiretroviral therapy had a DM incidence rate of 1.53/100 person-years; those reporting HAART containing a protease inhibitor (PI) had a rate of 2.50/100 person-years and those reporting non-PI-containing HAART a rate of 2.89/100 person-years. None of these rates differed from the HIV-uninfected women (1.96/100 person-years) substantially or beyond levels expected by chance. Among HIV-infected women, longer cumulative exposure to nucleoside reverse transcriptase inhibitors (NRTI) was associated with an increased risk of DM incidence compared with no NRTI exposure: relative hazard (RH) 1.81 [95% confidence interval (CI), 0.83-3.93] for > 0 to 3 years exposure and RH 2.64 (95% CI, 1.11-6.32) for > 3 years exposure. CONCLUSION: Longer cumulative exposure to NRTI was associated with increased DM incidence in HIV-infected women. Regular DM monitoring is advisable because NRTI form the backbone of effective antiretroviral therapy.

KW - Antiretroviral therapy

KW - Diabetes mellitus

KW - Fasting glucose

KW - HIV

KW - Nucleoside reverse transcriptase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=34547755171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547755171&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e32827038d0

DO - 10.1097/QAD.0b013e32827038d0

M3 - Article

VL - 21

SP - 1739

EP - 1745

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 13

ER -